Startup profile for CoFlo Medical: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

CoFlo Medical funding, valuation and investors

Develops injection devices for high-viscosity medicines.

Verified company research · funding, investors and latest developments

Keep track of CoFlo Medical

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Seed announced; instrument composition undisclosed

USD 6 million; instrument composition undisclosed · November 19, 2026

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

Not publicly disclosed

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

seed · San Francisco, California, United States

Investors in latest funding

Lead: J2 Ventures

Sources: latest funding · linkedin.com Last verified: 2026-11-22

Overview

CoFlo Medical develops drug-delivery devices based on core annular flow. Its cofounders are Simon Rufer, CEO; Vishnu Jayaprakash, chief business officer; and MIT professor Kripa Varanasi, chairman. The company describes its platform as a way to move concentrated medicines through needles with less resistance.

Why CoFlo Medical is interesting

Viscosity can limit how a concentrated medicine is delivered. CoFlo addresses that engineering constraint, but a useful drug/device combination still requires formulation compatibility and product-specific validation. Laboratory demonstrations and financing do not establish clinical outcomes or regulatory clearance.

Product & use cases

A lower-viscosity sheath surrounds the medicine as both fluids pass through the needle. The company says the sheath must be compatible with the drug and is injected along with it. Its website lists Gen One, Double Barrel and CO-AXL hub configurations for development with pharmaceutical partners.

  • Developing delivery configurations for concentrated, viscous drug formulations.
  • Evaluating compatible sheath fluids and injector configurations with pharmaceutical developers.

Key facts

  • CEO Simon Rufer announced a $6 million seed round on November 19, 2026. J2 Ventures separately confirms its lead role.
  • A 2025 SEC Form D reported $500,000 sold toward a $6 million offering. That historical disclosure is not added to the announced seed amount.

Funding history (newest first)

Seed announced; instrument composition undisclosed

2026-11-19 USD 6 million; instrument composition undisclosed

Source: Read source · linkedin.com

Investors in our directory

Funds linked from CoFlo Medical's profile — open a fund page for stage focus and related deal articles.

Notable stories

Market / IPO context

Editorial / static context — not a live quote.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.